DNA METHYLATION Cancer MICROBIOTA Crohn's disease Colon 18 FDG-PET/CT Inflammatory bowel diseases Disability Vedolizumab Colonic epithelial primary cells Contraindication Patient-reported outcome Consensus Fecal microbiota Microbiote Therapeutics Patients experience COLON-CANCER Safety Screening Helicobacter pylori Colorectal cancer Colibactin and lipids Dysbiosis Immune cells MALT Tailored therapy IL23 DNA methylation Acceptability Dysbiose Inflammatory Bowel Diseases Disease progression Thérapie ciblée Rituximab Surgery Algorithm Rituximab plus chlorambucil Clinical guidelines Disease Progression Inhibitor Neoadjuvant chemotherapy Inclusion Intestinal crypts Drug HIV Upper gastrointestinal tract Parvimonas micra Survival Ulcerative colitis Genes Anti-TNF agents CARCINOGENESIS Primary sclerosing cholangitis Colon cancer Cost effectiveness Inflammatory bowel disease Stricture Kidney diseases Over 80s Venous thromboembolism Cell adhesion Alkylating agents MARKER Résistance Clinical trial Colectomy IL12 Anti-TNF Méthylation Methylation Colorectal cancer Original Article Clinical Small molecules IBD Eligibility Immunosuppressant Eradication Bacteria Endoscopic treatment Tuberculosis Bactéries Gene expression PCR Biologics Resistance Effectiveness MORTALITY Monitoring RISK Maintenance therapy Crohn’s disease Epigénétiques Epigenetics Gènes Gene methylation T1118 translocation Heart disease risk factors Biomarker Ustekinumab Microbiota